Julimed - Company finances
|
EUR
|
2023
From: 2023-03-27
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|
|
Financial data
|
|||
| Sales revenue | 9,133 | 18,118 | 23,421 |
| Profit before tax | 1,065 | -145 | -98 |
| Net profit | 1,065 | -145 | -98 |
| Equity | 1,065 | 920 | 823 |
| Liabilities | 284 | 84 | 85 |
| Non-current assets | 0 | 0 | 0 |
| Current assets | 1,349 | 1,004 | 908 |
| Total assets | 1,349 | 1,004 | 908 |
|
Taxes paid
|
|||
| STI taxes | 64 | - | - |
|
Financial indicators
|
|||
| Revenue change y/y | - | +98.4% | +29.3% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 78.9% | -14.4% | -10.8% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 100.0% | -15.8% | -11.9% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 11.7% | -0.8% | -0.4% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 11.7% | -0.8% | -0.4% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.3 | 0.1 | 0.1 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | - | - | - |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Julimed - Social security debts
The company had no debts to Sodra
Julimed - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Julimed, MB (code 306283191) is a Small partnership engaged in traditional, complementary and alternative medicine activities. In 2025, the company generated revenue of €23.4K, up 29.3% year on year and 156.4% over two years, showing a clear expansion trend. Revenue increased from €9.1K in 2023 to €18.1K in 2024 and then to €23.4K in 2025. Profitability weakened after a positive 2023 result: net profit was €1.1K in 2023, moved to a loss of €145 in 2024, and remained slightly negative at €98 in 2025. The 2025 profit margin was -0.4%. At year-end 2025, total assets stood at €908, equity at €823, and liabilities at €85, indicating a strongly equity-financed balance sheet with an equity ratio of 90.6% and debt-to-equity of 0.10. Return on equity was -11.9% and return on assets -10.8% in 2025. Asset turnover was high relative to the asset base.